Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer.
The nonsteroidal anti-inflammatory drugs (NSAIDs) are found to be potential chemopreventive agents of colorectal cancer. Celecoxib, an NSAID with selective cyclooxygenase-2 inhibition, was proved to be effective for the prevention of colon cancer in patients with familial adenomatous polyposis (FAP) and sporadic polyps. In the light of this information, the present study was carried out to develop oral colon-targeting drug delivery systems for celecoxib using guar gum as a carrier. Matrix tablets containing various proportions of guar gum were prepared by wet granulation technique using starch paste as a binder. The tablets were evaluated for hardness, drug content and were subjected to in vitro drug release studies. The amount of celecoxib released from the matrix tablets at different time intervals was estimated by a HPLC method. Guar gum matrix tablets released only 2-4% of celecoxib in the physiological environment of stomach and small intestine depending on the proportion of guar gum used in the formulation. When the dissolution study was continued in simulated colonic fluids (rat caecal content medium), the matrix tablets containing 20% of guar gum released another 37% of celecoxib after degradation by the colonic bacterial action. The matrix tablets containing 30% of guar gum released about 24% of celecoxib in simulated colonic fluids indicating the susceptibility of the guar gum formulations to the rat caecal contents. The results of the study show that the matrix tablets containing either 20 or 30% of guar gum are most likely to target celecoxib for local action in the colon. The guar gum matrix tablets of celecoxib showed no change either in physical appearance, drug content or in dissolution pattern after storage at 40 degrees C/RH 75% for 6 months. Differential scanning calorimetry (DSC) studies indicated no possibility of interaction between celecoxib and guar gum/other formulation excipients.
Krishnaiah
Y S R
YS
Department of Pharmaceutical Sciences, Andhra University, India. krishnaysr112@rediffmail.com
Satyanarayana
V
V
Kumar
B Dinesh
BD
Karthikeyan
R S
RS
D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002152:Calorimetry, Differential Scanning; D000068579:Celecoxib; D002626:Chemistry, Pharmaceutical; D003106:Colon / Q000378:metabolism*; D015179:Colorectal Neoplasms / Q000517:prevention & control*; D004337:Drug Carriers; D004339:Drug Compounding / Q000379:methods; D016503:Drug Delivery Systems / Q000379:methods*; D005685:Galactans / Q000008:administration & dosage / Q000493:pharmacokinetics; D008351:Mannans / Q000008:administration & dosage / Q000493:pharmacokinetics; D053149:Plant Gums; D011720:Pyrazoles; D051381:Rats; D012995:Solubility; D013449:Sulfonamides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013607:Tablets
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004337:Drug Carriers; D005685:Galactans; D008351:Mannans; D053149:Plant Gums; D011720:Pyrazoles; D013449:Sulfonamides; D013607:Tablets; C007894:guar gum; D000068579:Celecoxib